Compared with monotherapy, co-administration of TEDbodies and agonistic OX40 antibody reduced the tumor volume by ~45% and increased the number of tumor-infiltrating anti-CMV CD8pos T cells. This evidence concerns the gene TNFRSF4 and neoplasm.